Viatris Inc. announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 (phentolamine ophthalmic solution 0.75%). The study focused on treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
MR-142 successfully achieved its primary endpoint, demonstrating a ≥15-letter (≥3-line) gain in Mesopic Low Contrast Distance Visual Acuity compared to placebo. The results also indicated a patient-reported functional benefit in addressing this condition.
No evidence of tachyphylaxis was observed in the study over the 6-week period, suggesting sustained efficacy. The trial was conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) and received Fast-Track Designation.
These positive outcomes confirm the potential of MR-142 to meet a critical unmet need, as there are currently no FDA-approved options for this specific condition. This development strengthens Viatris's eye care pipeline and positions MR-142 as a potential first-in-class treatment option, contributing to future revenue streams.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.